title: Optimizing conventional therapies for inflammatory bowel disease.
abstract: Conventional therapies remain the mainstay of treatment for most patients with inflammatory bowel disease (IBD), with only a minority of patients requiring biologic therapies. Recently, attention has focused on optimizing dosing strategies for biologic agents; however, of equal importance are recent advances in the optimization of conventional IBD therapies. Newer aminosalicylate formulations demonstrate similar efficacy with a reduced pill burden and less frequent dosing, while new corticosteroid preparations may retain efficacy with a significantly improved safety profile. The limited indications for antibiotics and probiotics have been further refined by recent data, although uncertainties remain. Advances in the understanding of thiopurine metabolism continue to improve dose optimization and the potential for deliberate therapeutic manipulation with adjunctive therapies. An improved knowledge of intracellular methotrexate metabolism may translate to similar opportunities in the future. This article discusses recent advances relevant to clinical practice today.
authors.affiliation: Department of Gastroenterology, The Alfred Hospital, Victoria, Australia. m.sparrow@alfred.org.au
authors.forename: Miles P
authors.initials: MP
authors.lastname: Sparrow
authors.forename: Peter M
authors.initials: PM
authors.lastname: Irving
authors.forename: Stephen B
authors.initials: SB
authors.lastname: Hanauer
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D019804:Mesalamine / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D007155:Immunologic Factors; D019804:Mesalamine